Monday, February 25, 2013

FDA approves Stivarga (regorafenib) for GIST

The FDA today announced the approval of Stivarga (regorafenib) for GIST. 

“Stivarga is the third drug approved by the FDA to treat gastrointestinal stromal tumors,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It provides an important new treatment option for patients with GIST in which other approved drugs are no longer effective.”

You can read the fill press release at the link below:

FDA approves Stivarga for advanced gastrointestinal stromal tumors

No comments:

Post a Comment

Comments are moderated. So there may be a delay before a comment appears on the site.